Athens Conference 2013



Conference Program

April 19-20, 2013











Mechanisms of Disease Development: New Challenges for Translational Research

APRIL 19-20, 2013

Organizing Committee: Katia Karalis Kostas Vekrellis Dimitris Beis Location: Biomedical Research Foundation of the Academy of Athens (BRFAA)

Program

Friday, April 19

- 08.30-08.40 Welcome Address Gregory D. Skalkeas, Professor-Academician, BRFAA President
- 08.40-11.00 Degeneration and Disease: Lessons from the CNS Chair: Efthimiopoulos S., Georgopoulos S.

Francisco Pan-Montojo, Institute of Anatomy, Medical Faculty Carl Gustav Carus, Dresden University of Technology, Dresden, Germany Implications of the enteric spreading hypothesis for the future treatment strategies in Parkinson's disease

Remy Sadoul, Grenoble Institut des Neurosciences, France Emerging role of neuronal exosomes in the central nervous system

Jia-Yi Li, Neural Plasticity and Repair Unit, Department of Experimental Medical Science, University of Lund, Sweden Beyond alpha-synuclein transfer: Pathology propagation in Parkinson's disease

Kelvin C. Luk, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania *Modeling alpha-synuclein misfolding and propagation in disease: lessons from inciting protein misbehavior*

- 11.00-11.30 Coffee break
- 11.30-13:00 (Continued) Degeneration and Disease: Lessons from the CNS Chair: Efthimiopoulos S., Georgopoulos S.

Adriano Aguzzi, Institute of Neuropathology, University Hospital of Zurich, Switzerland Functional and structural biology of prions

Round table: Are neurodegenerative diseases transmissible? Discussion Panel: Aguzzi A., Sadoul R., Sklaviadis T. Vekrellis K.







13.00-13.50 Lunch

Novel Approaches to Monitor Disease Progression 13.50-16.50 Chairs: Stefanis L., Kapaki E.

> John Cirrito, Department of Neurology, Washington University School of Medicine, St. Louis, USA

> Anti-depressants make plaques unhappy: Synaptic signaling pathways that regulate amyloidbeta metabolism in mice and humans

Brit Mollenhauer, Paracelsus-Elena Klinik and Georg August University Gottingen, Germany Quantification of alpha-synuclein in biological fluids as biomarker for Parkinson's disease

Omar El-Agnaf, Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, UAE

CSF alpha-synuclein in neurodegenerative disorders: an overview

Lydia Alvarez – Erviti, Clinical Neuroscience, Faculty of Brain Sciences, Institute of Neurology, UCL, UK

Parkinson's disease gene therapy by exosomes

Marcus Kruger, Biomolecular Mass Spectrometry, Max Planck Institute for Heart and Lung Research, Germany Global protein turnover analysis in living animals using stable isotope labeling

- 16.50-17.20 Coffee break
- 17.20-19.40 In silico modeling and model organisms

Chairs: Charalampopoulos J., Beis D., Tavernarakis N.

Andreas Deutsch, Department of Innovative Methods of the Computing Center for Information Services and High Performance Computing, Dresden University of Technology, Dresden, Germany

Mathematical analysis of cancer invasion

Eleftheria Pissadaki, MRC, Anatomical Neuropharmacology Unit, University of Oxford, UK Action potential propagation in the axons of dopamine neurons; clues to susceptibility in Parkinson's disease

Elizabeth Patton, Medical and Developmental Genetics, MRC, University of Edinburgh, UK Chemical and Genetic Approaches to Melanoma in Zebrafish

Antoine Depaulis, Grenoble Institut des Neurosciences, Centre de Recherche INSERM U836, Université Joseph Fourier, France

In search of novel therapeutic targets for Mesial Temporal Lobe Epilepsy (MTLE) using a global transcriptomic analysis







Saturday 20 April 2013

09.00-11.20 Mechanisms of Disease and Therapies Chairs: Margioris A., Kontoyiannis D.

Martin Ingelsson, Department of Public Health and Caring Sciences, Geriatrics; Molecular Geriatrics / Rudbeck laboratory, Uppsala University, Sweden *Immuno-based therapies for Alzheimer's disease and Parkinson's disease*

Triantafyllos Chavakis, Division for Vascular Inflammation, Diabetes and Kidney, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany *Leukocyte recruitment in inflammatory disease*

Patrick Griffin, Department of Molecular Therapeutics, The Scripps, Research Institute, Florida, and Translational Research Institute, Kellogg School of Science and Technology, USA *Mechanism of Action of Novel Insulin Sensitizers*

Roy G Smith, Department of Metabolism and Aging, The Scripps, Research Institute, Florida, USA

Disorders of Dopamine Transmission: Ghrelin Receptor (GHSR1a) Antagonists as Allosteric Modulators

- 11.20-11.50 Coffee break
- 11.50-13.15 Mechanisms of disease and Therapies Chairs: Margioris A., Kontoyiannis D.

Jonathan Seckl, Molecular Medicine, Endocrinology Unit, Centre for Cardiovascular Science, University of Endiburgh, UK *Intracellular glucocorticoid metabolism: a tale in translational medicine*

Round table: STRESS and METABOLISM at the center of disease pathogenesis Discussion Panel: Griffin P., Smith R., Chrousos G., Karalis K

- 13.15-14.05 Lunch
- 14.05-16.35 Stem cells and other approaches in treating disease Chair: Thanos D.

Lee Rubin, Harvard University Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, USA *Identifying New Therapeutics for Motor Neuron Disease*

Bruno Péault, BHF Center for Vascular Science, University of Edinburgh, UK and Department of Orthopaedic Surgery, UCLA School of Medicine, USA *Understanding the Natural History of Mesenchymal Stem Cells to Improve their Medical Utilization*

Afsaneh Gaillard, Cellular Therapies in Brain Diseases group, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, INSERM U1084, Poitiers, France *Rewiring the brain with cell transplantation*







Matsas Rebecca, Cellular and Molecular Neurobiology, Institute Pasteur, Greece Stem cells for modeling and treating CNS disease and neurotrauma

- 16.35-17.05 Coffee break
- 17.05-20.10 Stem cells and other approaches in treating disease

Chairs: Thomaidou D., Politis P.

Nikos Mazarakis, Gene therapy, Department of Medicine, Imperial College, UK *Translational gene therapy approaches for neurodegenerative diseases using Lentiviral vectors*

Tilo Kunath, Centre for Regenerative Medicine, University of Edinburgh Modelling Parkinson's disease and dementia with iPS cells and transgenic human ES cells

Evangelos Kiskinis, Faculty of Arts & Sciences, Stem Cell and Regenerative Biology, Harvard University, USA

Motor neurons generated from ALS patient-specific iPS cells recapitulate key aspects of the disease

Richard Wade Martins, Department Of Physiology, Anatomy and Genetics, University of Oxford, UK

Common mechanisms underlying Parkinson's disease revealed by analysis of iPS-derived patient dopamine neurons

Round table: How close are we to use stem cells for treating disease? Discussion Panel: Rubin L., Péault B., Mazarakis N., Thanos D.

